The study
analyzed that the BET inhibitors pipeline comprised 38 drug candidates in
different stages of development. The high prevalence of cancer across the globe
fuels the extensive research and development for BET inhibitors.
BET inhibitor constitutes that class of drugs,
which prevents interactions between BET proteins, and transcription factors and
acetylated histone. This results in immunosuppressive and anti-cancer
properties of BET inhibitor. Inhibition of BET proteins offered a new
therapeutic approach for the treatment of cancer, cardiovascular diseases and
other diseases.
Download
Free Sample of This Research Report: https://www.psmarketresearch.com/market-analysis/bet-inhibitors-pipeline-analysis/report-sample
As per the
findings of the research, maximum BET inhibitor drug candidates target BRD4 and
are being developed to be administered by oral route.
Resverlogix
Corp. is developing its drug candidate in highest stage of development for the
treatment of diabetes mellitus, coronary artery disease and cardiovascular
diseases. The product is also in different phases of development for different
indications, such as atherosclerosis and dyslipidemia.
Make
Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=bet-inhibitors-pipeline-analysis
The
research finds that different companies are collaborating for the development
of BET inhibitors with better efficacy.
Some of
the key players developing BET inhibitors are Resverlogix Corp.,
GlaxoSmithKline plc, Bristol-Myers Squibb Company and others.
Contact:
Mr. Kundan Kumar
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +18887787886
(USA/Canada)
Email: enquiry@psmarketresearch.com
